Advanced Search

NCI-H1770 [H1770] (ATCC® CRL-5893™)

Organism: Homo sapiens, human  /  Cell Type: neuroendocrine  /  Tissue: lung; derived from metastatic site: lymph node  /  Disease: stage 4, carcinoma; non-small cell lung cancer

Permits and Restrictions

View Permits View Restrictions
Organism Homo sapiens, human
Tissue lung; derived from metastatic site: lymph node
Cell Type neuroendocrine
Product Format frozen
Culture Properties suspension, multicell aggregates
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease stage 4, carcinoma; non-small cell lung cancer
Age 57 years
Gender male
Ethnicity Caucasian
Derivation
The line was established in November 1987.
Clinical Data
57 years
Caucasian, White
male
The tissue donor was a non-smoker.
Comments
A lymphoblastoid line from the same patient is available as ATCC CRL-5960.
Complete Growth Medium ACL-4 medium (serum-free)
The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
  • 0.02 mg/ml insulin
  • 0.01 mg/ml transferrin
  • 25 nM sodium selenite (final conc.)
  • 50 nM Hydrocortisone (final conc.)
  • 1 ng/ml Epidermal Growth Factor (do not filter)
  • 0.01 mM ethanolamine (final conc.)
  • 0.01 mM phosphorylethanolamine (final conc.)
  • 100 pM triiodothyronine (final conc.)
  • 0.5% (w/v) bovine serum albumin (final conc.)
  • 10 mM HEPES
  • 0.5 mM sodium pyruvate (final conc.)
  • extra 2mM L-glutamine (for final conc. of 4.5mM)
Subculturing
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium.
Cells grow as floating aggregates of round cell clusters.
Medium Renewal: Add fresh medium as cell density increases.
Cryopreservation
Culture medium, 85%; fetal bovine serum, 10%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 11,13
D13S317: 13
D16S539: 12,13
D5S818: 11,12
D7S820: 11
THO1: 9
TPOX: 11
vWA: 18,19
Name of Depositor AF Gazdar, JD Minna
Year of Origin 1987
References

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
Other Documentation
Other Document
p53 Hotspot Mutation Data
Restrictions

The line is available with the following restrictions:

  1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied.
  2. Any proposed commercial use of the these cells, or their products, must first be negotiated with the National Cancer Institute (NCI).  For further information, please contact NCI’s Technology Transfer Center at NCI_TTC_Contact@mail.nih.gov or by phone at (240)-276-5514.
References

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.